View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 55,000 shares at 902.625DKK and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Bic Sa: 1 director

A director at Bic Sa sold 2,982 shares at 64.990EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

GSK: 1 director

A director at GSK sold 6,000 shares at 1,702p and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close p...

 PRESS RELEASE

Arkema : Déclaration relative au nombre total de droits de vote et d’a...

PARIS--(BUSINESS WIRE)-- Regulatory News: Arkema (Paris:AKE) : A la date du Nombre d’actions composant le capital Nombre théorique des droits de vote (y compris actions auto-détenues) Nombre réel de droits de vote (déduction faite des actions auto détenues) 30/04/2024 75 043 514 93 092 627 92 763 726   Consultez la version source sur businesswire.com :

Jerôme Bodin
  • Jerôme Bodin

ODDO BHF Small & MIDCAP MORNING NEWS - 03/05/2024

Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...

Jerôme Bodin
  • Jerôme Bodin

ODDO BHF Small & MIDCAP MORNING NEWS - 05/03/2024

Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)

This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...

Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian

Neoen : Q1 2024 revenue in line, guidance confirmed and still question...

>Outperform rating and target price of € 35.50 unchanged - The Q1 2024 revenue release was fully in line with our expectations (€ 141.4m vs € 144.9m estimated). The group also confirmed its 2024 guidance and that for 2030. We maintain our Outperform rating and target price of € 35.5 still based on the average of a sum-of-the-parts (€ 35.4) and a DCF (€ 35.6 and unchanged growth to infinity of 1.80%). The current market capitalisation points to a certain upside from b...

Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian

Neoen : CA T1 24 en ligne, guidances confirmées et toujours des questi...

>Opinion Surperformance et OC 35.50 € inchangés - La publication du chiffre d’affaires du T1 24 est ressortie parfaitement en ligne avec nos anticipations (141.4 M€ vs 144.9 M€ estimés). Le groupe confirme également ses guidances 2024 ainsi que celles de 2030. Nous maintenons notre recommandation Surperformance et notre objectif de cours de 35.5 € toujours fondé sur une moyenne entre une somme des parties (35.4 €) et un DCF (35.6 € et taux de croissance à l’infini in...

Rune Majlund Dahl
  • Rune Majlund Dahl

Novo Nordisk (Buy, TP: DKK1100.00) - Small guidance raise

Q1 LCY figures beat consensus due to US rebate adjustments related to 2023 adding c5%-points to LCY growth and low SG&A cost boosting EBIT growth in Q1. Wegovy sales were below consensus but above our forecast, and we have therefore adjusted our rebate assumptions for 2024. The 2024 guidance was raised to LCY sales growth of 19–27% (18–26%) and LCY operating profit growth of 22–30% (21–29%). We reiterate our BUY and DKK1,100 target price.

Airbus SE: Update following the rating outlook change to positive

Our credit view of this issuer reflects its very strong balance sheet and liquidity and its dominant market position in the single-aisle market.

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/02/2024

BBVA proposes merging with Banco Sabadell to create a European leaderUnited Group: e& has considered a potential acquisition of United Group (Bloomberg)>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 02/05/2024

BBVA propose à Sabadell une fusion afin de créer un leader européenUnited Group : e& envisagerait une possible acquisition de United Group (Bloomberg)>...

Jean Danjou ... (+3)
  • Jean Danjou
  • Oliver Metzger
  • Thomas Zlowodzki

ODDO BHF Small & MIDCAP MORNING NEWS - 02/05/2024

Nous sortons GALP de notre liste ODDO BHF European Large Caps. La valeur a réalisé une performance de +31,3% depuis son entrée le 20 mars dernier. Notre analyste adopte ce jour une opinion Neutre (vs Surperformance) sur la valeur qui a atteint notre objectif de cours. - ...

Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian

Neoen : Q1 2024 figures fully in line and guidance reaffirmed

>Q1 2024 revenue fully in line - The group has just announced Q1 2024 revenue of € 141.4m, in line with our forecast of € 144.9m, down 8% vs Q1 2023 and 6% at constant forex. This trend was largely due to an unfavourable comparison base linked to the more limited contribution from a number of assets that benefited from revenues upstream of long-term contracts and which have since entered the long-term contractual framework from Q2 2023, in Finland and Australia. Prod...

Louis Boujard ... (+3)
  • Louis Boujard
  • CFA
  • Philippe Ourpatian

Neoen : Un chiffre d’affaires T1 24 parfaitement en ligne et des guida...

>Un chiffre d’affaires T1 24 parfaitement en ligne - Le groupe vient d’annoncer un chiffre d’affaires de 141,4 M€ au T1 24, en ligne avec nos attentes de 144.9 M€, en recul de 8% par rapport au T1 23 et de 6% à taux de change constants. Cette évolution s’explique principalement par un effet de base défavorable lié à la moindre contribution de plusieurs actifs ayant bénéficié de revenus en amont de contrats à long terme et entrés depuis dans le cadre contractuel de lo...

 PRESS RELEASE

EQS-News: USA: Nordex Group erhält Auftrag über 148 MW für Turbinen de...

EQS-News: Nordex SE / Schlagwort(e): Auftragseingänge USA: Nordex Group erhält Auftrag über 148 MW für Turbinen des Typs N149/5.X 02.05.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hamburg, 2. Mai 2024. Die Nordex Group hat einen Auftrag über 25 Turbinen des Typs N149/5.X der Delta 4000-Serie aus den Vereinigten Staaten erhalten. Die Anlagen werden auf 89 Meter hohen erdbebensicheren Türmen in einem nicht genannten Windpark in Kalifornien installiert. Die Auslieferung ist für Sommer 2025 geplant, die Inbetriebnahme bis...

 PRESS RELEASE

EQS-News: USA: Nordex Group receives order for 148 MW for N149/5.X tur...

EQS-News: Nordex SE / Key word(s): Incoming Orders USA: Nordex Group receives order for 148 MW for N149/5.X turbines 02.05.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, 2 May 2024. The Nordex Group has received an order for N149/5.X turbines from the United States and will be supplying 25 of its Delta 4000 series models. The turbines will be installed with an 89m seismic tower at an undisclosed wind farm in California. Deliveries are scheduled for the summer of 2025 with commissioning by the end of the year. The cont...

Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update May 2024 : Adding Fugro, Removing Arcadis

In this May edition of our Dynamic Top Pick List we replace Arcadis by Fugro. Arcadis continues to deliver consistently on its promises and is working hard to realise its 2026 margin targets via cross selling, leveraging its global engineering platform and numerous self-help measures. In spite of this we remove Arcadis from our Dynamic Top Pick List as the recent & strong share price performance leaves little room for further short term triggers As a service provider to the energy industry, Fu...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch